PT  - JOURNAL ARTICLE
AU  - Smruti Karale
AU  - Vikas Bansal
AU  - Janaki Makadia
AU  - Muhammad Tayyeb
AU  - Hira Khan
AU  - Shree Spandana Ghanta
AU  - Romil Singh
AU  - Aysun Tekin
AU  - Abhishek Bhurwal
AU  - Hemant Mutneja
AU  - Ishita Mehra
AU  - Rahul Kashyap
TI  - An Updated Systematic Review and Meta-Analysis of Mortality, Need for ICU admission, Use of Mechanical Ventilation, Adverse effects and other Clinical Outcomes of Ivermectin Treatment in COVID-19 Patients
AID  - 10.1101/2021.04.30.21256415
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.30.21256415
4099  - http://medrxiv.org/content/early/2021/09/17/2021.04.30.21256415.short
4100  - http://medrxiv.org/content/early/2021/09/17/2021.04.30.21256415.full
AB  - Importance Repurposing Ivermectin, a known anti-parasitic agent, for treating COVID-19 has demonstrated positive results in several studies. We aim to evaluate the benefit and risk of Ivermectin in COVID-19.Methods We conducted a systematic search for full-text manuscripts published from February 1, 2020, to August 15th, 2021 focusing on Ivermectin therapy against COVID-19. The primary outcomes were mortality, need for intensive care unit (ICU) admission; secondary outcomes were - adverse effects, need for mechanical ventilation, viral clearance, time to viral clearance, need for hospitalization, and length of hospital stay. Random-effects models were used for all analyses.Results We included a total of 52 studies (n=17561) in the qualitative analysis, out of these, 44 studies (n=14019) were included in the meta-analysis. In the mortality meta-analysis (N=29), odds of death were lower in the Ivermectin-arm compared to control (OR 0.54, p=0.009). Although lower odds of mortality were observed in various subgroup analyses of RCTs, they did not reach statistical significance: therapeutic RCTs: mild-moderate COVID-19 (OR 0.31, p=0.06), therapeutic RCTs: severe/critical COVID-19 (OR 0.86, p=0.56), inpatient RCTs: mild-moderate COVID-19 (OR 0.18, p=0.08), inpatient RCTs: severe/critical COVID-19 (OR 0.86, p=0.56). Ivermectin, mostly as adjuvant therapy, was associated with higher odds of viral clearance (N=22) (OR 3.52, p=0.0002), shorter duration to achieve viral clearance (N=8) (MD - 4.12, p=0.02), reduced need for hospitalization (N=6) (OR 0.34, p=008).Conclusion Our meta-analysis suggests that the mortality benefit of Ivermectin in COVID-19 is uncertain. But as adjuvant therapy, Ivermectin may improve viral clearance and reduce the need for hospitalization.What We Already Know about This TopicCOVID-19 is an ongoing global pandemic, for which Ivermectin has been tried on a therapeutic and prophylactic basis.Results from several clinical trials and observational studies suggest that Ivermectin may improve survival and clinical outcomes with a good safety profile when compared with other treatments; however, the current evidence is limited..What This Article Tells Us That Is NewThis systematic review and meta-analysis provide a summary of the latest literature on the efficacy and safety of Ivermectin use for COVID-19.Based on our analysis of the latest evidence, we found that Ivermectin’s benefit in reducing mortality cannot be concluded with confidence. However, as an adjuvant therapy it may help reduce the need for hospitalization, duration for viral clearance while increasing the likelihood of achieving viral clearance.We need more high-quality data for conclusive evidence regarding the benefit of Ivermectin in reducing the need for ICU admissions, mechanical ventilation and duration of hospital stay in COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere is no financial disclosure related to this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB approval was required for this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is available on our site.ARDSAcute respiratory distress syndromeCDCCenters for Disease Control and PreventionCOVID-19Coronavirus Disease 2019DNADeoxyribonucleic AcidEMAEuropean Medicines AgencyFDAFood and Drug AdministrationICUIntensive Care UnitIRBInstitutional Review BoardNIHNational Institutes of HealthRCTRandomized controlled trialRNARibonucleic AcidRT-PCRReverse Transcription Polymerase Chain ReactionIMPImportinSARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2WHOWorld Health Organization